William Moore Acquires 28,157 Shares of IRIDEX (NASDAQ:IRIX) Stock

IRIDEX Corporation (NASDAQ:IRIX) Director William Moore bought 28,157 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was purchased at an average cost of $0.97 per share, with a total value of $27,312.29. Following the acquisition, the director directly owned 228,831 shares in the company, valued at $221,966.07. This trade represents a 14.03% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

IRIDEX Trading Up 2.7%

Shares of IRIX stock opened at $0.95 on Thursday. The company has a debt-to-equity ratio of 62.29, a quick ratio of 1.34 and a current ratio of 1.96. The stock has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $1.12. The firm has a market capitalization of $16.36 million, a PE ratio of -2.88 and a beta of 0.56. IRIDEX Corporation has a 52-week low of $0.78 and a 52-week high of $1.95.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings data on Wednesday, November 12th. The medical equipment provider reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). IRIDEX had a negative return on equity of 386.93% and a negative net margin of 10.95%.The business had revenue of $12.48 million during the quarter, compared to the consensus estimate of $13.10 million.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of IRIDEX in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On IRIDEX

Several large investors have recently made changes to their positions in IRIX. Apexium Financial LP boosted its stake in IRIDEX by 53.0% during the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 34,834 shares during the last quarter. Susquehanna International Group LLP increased its stake in IRIDEX by 46.2% in the 3rd quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 17,834 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of IRIDEX by 62.7% during the 3rd quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock worth $126,000 after acquiring an additional 42,202 shares in the last quarter. Finally, Thompson Davis & CO. Inc. bought a new position in shares of IRIDEX during the 2nd quarter valued at approximately $50,000. 20.10% of the stock is owned by institutional investors.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.